Anzeige
Mehr »
Freitag, 31.10.2025 - Börsentäglich über 12.000 News
Weltweiter Kaliboom treibt Nachfrage - ACM positioniert sich im 93,5 Mrd. USD-Markt bis 2032!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PHD4 | ISIN: US4525EP1011 | Ticker-Symbol: 10VA
Tradegate
30.10.25 | 17:22
0,680 Euro
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
IMMUNIC INC Chart 1 Jahr
5-Tage-Chart
IMMUNIC INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,6900,71030.10.
0,6690,69130.10.

Aktuelle News zur IMMUNIC Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiEQS-News: Immunic AG: Immunic to Participate in Industry and Investor Conferences in November242Issuer: Immunic AG / Key word(s): Conference Immunic to Participate in Industry and Investor Conferences in November 29.10.2025 / 11:30 CET/CEST The issuer is solely...
► Artikel lesen
IMMUNIC Aktie jetzt für 0€ handeln
01.10.EQS-News: Immunic AG: Immunic to Participate in Scientific and Investor Conferences in October518Issuer: Immunic AG / Key word(s): Conference Immunic to Participate in Scientific and Investor Conferences in October 01.10.2025 / 12:30 CET/CEST The issuer is solely...
► Artikel lesen
25.09.IMMUNIC, INC. - 8-K, Current Report13
25.09.Immunic's MS drug shows promise with disability improvement data18
25.09.EQS-News: Immunic AG: Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis301Issuer: Immunic AG / Key word(s): Conference/Study results Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple...
► Artikel lesen
09.09.Immunic sichert US-Patent für Dosierung seines Multiple-Sklerose-Medikaments47
09.09.Immunic receives patent for multiple sclerosis treatment dose strengths1
09.09.EQS-News: Immunic AG: Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis433Issuer: Immunic AG / Key word(s): Patent Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple...
► Artikel lesen
04.09.EQS-News: Immunic AG: Immunic to Participate in Investor and Scientific Conferences in September391Issuer: Immunic AG / Key word(s): Conference Immunic to Participate in Investor and Scientific Conferences in September 04.09.2025 / 12:30 CET/CEST The issuer is solely...
► Artikel lesen
02.09.B.Riley lowers Immunic stock price target to $4 as catalyst-rich period approaches12
02.09.Immunic: B.Riley senkt Kursziel vor katalysatorreicher Phase auf 4 $31
27.08.IMMUNIC, INC. - S-8, Securities to be offered to employees in employee benefit plans19
07.08.IMMUNIC, INC. - 10-Q, Quarterly Report25
07.08.IMMUNIC, INC. - 8-K, Current Report14
07.08.EQS-News: Immunic AG: Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update527Issuer: Immunic AG / Key word(s): Quarter Results Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update 07.08.2025 / 12:30 CET/CEST The...
► Artikel lesen
11.07.Immunic: Verwaltungsrat genehmigt bis zu 35 Millionen Stock Appreciation Rights für Mitarbeiter92
11.07.IMMUNIC, INC. - 8-K, Current Report10
24.06.Immunic Posts Positive Long-Term OLE Data From Phase 2 Trial Of Vidofludimus Calcium In RRMS35
24.06.Immunic reports low disability worsening rates in MS drug trial15
24.06.EQS-News: Immunic AG: Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis431Issuer: Immunic AG / Key word(s): Study/Study results Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in...
► Artikel lesen
Weiter >>
46 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,5